

Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

Horizon Europe

● IN ATTESA

Codice

HORIZON-HLTH-2027-01-DISEASE-06

Ambito

Internazionale

Località

Europa

Curatore

Marlene Faria

DETTAGLI FINANZIARI

Tipo di supporto

Fondo perduto

Tasso Massimo di Finanziamento

100%

Budget

37.3M€

Valore di Progetto Ammissibile

Up to 10M€

DATE E SCADENZE

Data di Pubblicazione

16 ottobre 2026

Data di Apertura

29 ottobre 2026

Fase unica

17 febbraio 2027 alle ore 17:00 GMT+1

DESCRIZIONE

Objectives

This topic aims to advance existing prophylactic and therapeutic monoclonal antibody candidates against emerging and re-emerging Flavivirus infections. The objective is to make experimental antibodies available for further clinical development and increase the number of treatment options that could be rapidly deployed during future epidemics or pandemics. The topic also supports the implementation of the European Medical Countermeasures Strategy and seeks to strengthen European leadership and preparedness in antiviral research and development.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA). The topic has an indicative budget of €37.3 million, with approximately four projects expected to be funded. The anticipated EU contribution ranges from €9 million to €10 million per project, although proposals requesting different

amounts may be considered where appropriately justified. As an RIA, the action may receive funding of up to 100% of eligible costs, in accordance with Horizon Europe rules.

SPESE AMMISSIBILI

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

IDONEITÀ

Settori Idonei
Salute e Life Sciences

Modalità di Candidatura
Aggregata / Partenariato

Tipologie Aziendali

- Microimpresa
- PMI
- Small Mid-Cap
- Mid-Cap
- Grande impresa
- Enti di ricerca
- Enti privati non profit
- Enti pubblici

Tipi di Azione

- Research and Innovation Action
- Collaborative Project

DETTAGLI PROGRAMMA UE

ID Bando
HORIZON-HLTH-2027-01-DISEASE-06

Cluster
Health

Destinazione
D3. Tackling diseases and reducing disease burden

Modalità di Presentazione
Single-stage

Contributo UE
Around €9,000,000.00 to €10,000,000.00 per project

Progetti Previsti
4

Regola del Tasso di Finanziamento

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

LINK UFFICIALI

Regolamento Ufficiale

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-06?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2027-01-DISEASE-06&isExactMatch=true&status=31094501,31094502,31094503>

Pagina Grantavia

<https://grantavia.com/it/incentives/development-of-monoclonal-antibodies-to-prevent-and-treat-infections-from-flaviviruses>

Prenota un incontro

<https://bookings.cloud.microsoft/book/Prenotaunappuntamento@epsa.com/?ismsaljsauthenabed>